# Clearmind Medicine Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Clearmind Medicine Inc.). ## Overview Clearmind Medicine Inc. is a U.S.-listed clinical-stage biotechnology company focused on discovering and developing non-hallucinogenic neuroplastogen-derived therapeutics. Its work centers on patented psychedelic-inspired compounds, including MEAI and CMND-100, for alcohol use disorder, binge-related behaviors, addiction, weight management, PTSD, and other central nervous system disorders, with operations and intellectual property activity spanning North America, Europe, and Asia. ## Products & services • MEAI-based neuroplastogen therapeutics • CMND-100 CNS therapeutic program • Binge-behavior regulation compounds • PTSD and mental-health compound candidates • Intellectual property licensing and patent portfolio - **Lead neuroplastogen programs** (50%) — Drug candidates based on non-hallucinogenic psychedelic-inspired compounds such as MEAI and CMND-100. - **Addiction and binge-behavior therapeutics** (20%) — Programs aimed at alcohol use disorder, binge drinking, binge eating, and gambling-related behaviors. - **Mental health and PTSD compounds** (15%) — Research programs targeting PTSD and other psychiatric or stress-related disorders. - **Weight management therapeutics** (5%) — Compounds and formulations being developed for appetite, overeating, and related weight-control uses. - **Licensing and intellectual property** (10%) — Patent filings, patent grants, and exclusive rights obtained through licensing agreements. - MEAI-based neuroplastogen therapeutics - CMND-100 CNS therapeutic program - Binge-behavior regulation compounds - PTSD and mental-health compound candidates - Intellectual property licensing and patent portfolio ## Customers Clearmind primarily serves pharmaceutical and biotech stakeholders rather than mass-market end users: the near-term customer base is best understood as regulators, development partners, licensors, and future healthcare providers that would adopt its medicines if approved. In the commercialization phase, its products would ultimately be prescribed or recommended for patients with alcohol use disorder, binge-related behaviors, PTSD, and other CNS conditions. The company also relies on research and intellectual-property partners, including universities and licensing counterparties, to build and advance its pipeline. - **Patients with binge-related disorders** (primary) — Future end users of therapies for alcohol use disorder, binge drinking, binge eating, and gambling-related behaviors. - **Psychiatry and addiction clinicians** (primary) — Prescribers who would use approved products to treat mental health and substance-use disorders. - **Licensing and research partners** (secondary) — Academic and IP counterparts that supply inventions, compounds, or collaborative development rights. - **Pharmaceutical commercialization partners** (secondary) — Potential partners that could help fund late-stage development or market approved candidates. - Patients with alcohol use disorder and related binge behaviors - Future prescribing clinicians in psychiatry and addiction medicine - Research and licensing partners such as academic institutions - Potential pharmaceutical partners for development or commercialization - Healthcare systems treating mental health and CNS disorders ## Geography Clearmind is incorporated and listed in the United States, with principal executive offices in Vancouver, Canada, and investor-facing activity across North America. Its patent strategy is international, with disclosed protection in the United States, Europe, and Hong Kong, reflecting an attempt to secure future commercialization rights in multiple major markets. The company’s business is therefore geographically defined more by where its intellectual property is protected and where future regulatory approvals may be sought than by current commercial sales. - U.S. listing on Nasdaq under CMND - Principal executive offices in Vancouver, Canada - Patent coverage in the United States and Europe - Hong Kong filing expands Asia market access - Global rights via Yissum licensing agreement ## Strategy Clearmind’s strategy is to build a broad, defensible intellectual-property estate around non-hallucinogenic psychedelic-derived compounds and use it to support future drug development and commercialization. The company is also extending patent coverage into multiple jurisdictions so that any eventual product can be protected across large addressable markets. Its licensing model with Yissum gives it exclusive global rights to develop and commercialize compounds while it advances the program through regulatory pathways. - **Broaden global patent coverage** (short-term) — Protects the company’s compounds and strengthens future partnering leverage. - **Advance lead neuroplastogen candidates** (medium-term) — Pipeline progress is required before any meaningful commercial opportunity can emerge. - **Secure development and commercialization pathways** (medium-term) — Multiple regulatory and product pathways can improve the odds of eventual market entry. - Expand patent protection across major global jurisdictions - Advance MEAI and CMND-100 through development milestones - Target addiction and mental-health indications with unmet need - Leverage exclusive licensing rights from Yissum - Position compounds for regulated medicine, food, or supplement paths ## Risks Clearmind faces the typical risks of clinical-stage biotechnology, where product candidates may fail in development, regulatory approval may be delayed, and patent protection may not translate into commercial products. Its reliance on a small number of compounds and on external licensing and valuation judgments also creates concentration risk and ongoing financing sensitivity. Because it has no disclosed commercial product sales in the provided materials, execution risk is centered on proving clinical utility, protecting IP, and funding development long enough to reach commercialization. - **Clinical development failure** [critical] — The company’s value depends on proving that neuroplastogen candidates are safe and effective. - **Regulatory approval uncertainty** [high] — Drug candidates must satisfy multiple regulatory hurdles before commercialization. - **Intellectual property dependence** [high] — The strategy relies on patents and exclusive licensing to secure market exclusivity. - **Financing and dilution risk** [high] — Clinical-stage biotechnology typically requires repeated external capital raises. - Clinical trial failure or weak efficacy could stop pipeline value creation - Regulatory delays may push out commercialization timelines - Patent disputes or weak protection could reduce exclusivity - Dependence on external licensing and IP counterparties adds concentration risk - Derivative warrants and convertible loans add valuation and funding risk ## Accounting The key accounting issue in the provided materials is fair-value accounting for derivative warrant liabilities and assets, which can create period-to-period volatility in reported results as assumptions change. The company also relies on judgment-heavy estimates around going concern, lease liabilities, related-party balances, and convertible loans, all of which matter because it is still in the development stage and does not yet have stable operating revenue. Because its future economics depend heavily on IP and development success, investors should watch for impairment, valuation, and financing-related accounting judgments. - **Derivative warrant liabilities and assets** — Can materially affect reported profit or loss - **Black-Scholes and binomial valuation assumptions** — Changes can significantly shift warrant valuations - **Going concern judgment** — Important for liquidity and solvency analysis - **Convertible loans and related-party liabilities** — Influences leverage and near-term obligations - Fair-value changes in derivative warrant liabilities can move earnings - Black-Scholes and binomial inputs drive valuation sensitivity - Convertible loans affect capital structure and liquidity disclosure - Going concern judgment is important for a development-stage biotech - Lease and related-party balances affect short-term obligations --- *Last updated: 2026-09-28T11:58:12.962883+00:00*